Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021
Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells with the goal of overcoming PD-1 resistance in certain tumor types
Lund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that data highlighting the efficacy and safety of Neo-X-Prime™ bsAbs and how Alligator’s lead compound targeting CD40 and CEA meets key needs in Immuno-oncology, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs virtually on November 10th – 14th, 2021.
“We are very excited by this data as it reinforces the robust potential of our proprietary Neo-X-Prime™ platform. The data shows that simultaneous CD40 engagement and delivery of neoantigen-containing tumor exosomes to antigen-presenting cells mediates an expansion of the tumor-specific T cell repertoire, resulting in potent anti-tumor effects," stated Karin Hagerbrand, PhD., Senior Scientist at Alligator Bioscience. “This is another step forward in the development of our platform technology and we are enthusiastic over the data presented on our lead Neo-X- Prime™ compound, targeting CD40 and CEA.”
Session: Poster Hall
Title: Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
Presenter: Karin Hagerbrand, PhD.
The above poster presentation will be available online at www. www.alligatorbioscience.se on Saturday, November 13, 2021.
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Out-licensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.